Drug Type Live attenuated vaccine, Prophylactic vaccine |
Synonyms- |
Target |
Action inhibitors |
Mechanism Respiratory syncytial virus F protein inhibitors |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Human Metapneumovirus Infection | Preclinical | Canada | 19 Jun 2024 | |
| Human Metapneumovirus Infection | Preclinical | France | 19 Jun 2024 | |
| Respiratory Syncytial Virus Infections | Preclinical | Canada | 19 Jun 2024 | |
| Respiratory Syncytial Virus Infections | Preclinical | France | 19 Jun 2024 |





